Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch
Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the launch of the company's new GLP-1 pill for obesity in the U.S. In a Friday note, TD Cowen analysts called it a "solid start" but cautioned that they need to see more data to fully assess what early demand is like for the Wegovy pill.
Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch
Novo Nordisk's Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts on Friday showed, as investors closely watch to see if the firm can ram home its first-mover advantage against rival Eli Lilly in a competitive weight-loss market.
Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss
Britain's regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.
Novo shares jump 7% ahead of US prescription data for Wegovy pill
Shares of Novo Nordisk rose 7% on Friday, touching their highest level since September, and were among the top gainers in Europe, ahead of U.S. prescription data expected from analysts on the Danish drugmaker's Wegovy pill.
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
Novo Nordisk (NVO) concluded the recent trading session at $58.98, signifying a -1.12% move from its prior day's close.
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits
Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) concluded the recent trading session at $57.34, signifying a +1.36% move from its prior day's close.
Novo Nordisk: A Pill For Growth
Novo Nordisk is rated Buy, with the FDA-approved Wegovy pill seen as a potential catalyst to reignite growth and recapture market share. NVO faces headwinds from lower pill pricing, potential cannibalization, and competition from LLY, but aggressive distribution and cost management may drive upside surprises. Despite a forecasted 2% revenue decline in 2026, NVO maintains robust >47% EBITDA margins and is expected to generate over $10bn in FCF post-Catalent acquisition.
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
